Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN), is 'Incrementally Positive'
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $435.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
